The R22X Mutation of the SDHD Gene in Hereditary Paraganglioma Abolishes the Enzymatic Activity of Complex II in the Mitochondrial Respiratory Chain and Activates the Hypoxia Pathway
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Hereditary paragangliomas are usually benign tumors of the autonomic nervous system that are composed of cells derived from the primitive neural crest. Even though three genes (SDHD, SDHC, and SDHB), which encode three protein subunits of cytochrome b of complex II in the mitochondrial respiratory chain, have been identified, the molecular mechanisms leading to tumorigenesis are unknown. We studied a family in which the father and his eldest son had bilateral neck paragangliomas, whereas the second son had a left carotid-body paraganglioma and an ectopic mediastinal pheochromocytoma. A nonsense mutation (R22X) in the SDHD gene was found in these three affected subjects. Loss of heterozygosity was observed for the maternal chromosome 11q21-q25 within the tumor but not in peripheral leukocytes. Assessment of the activity of respiratory-chain enzymes showed a complete and selective loss of complex II enzymatic activity in the inherited pheochromocytoma, that was not detected in six sporadic pheochromocytomas. In situ hybridization and immunohistochemistry experiments showed a high level of expression of markers of the angiogenic pathway. Real-time quantitative reverse transcriptase (RT)-PCR measurements confirmed that vascular endothelial growth factor and endothelial PAS domain protein 1 mRNA levels were significantly higher (three- and sixfold, respectively) than those observed in three sporadic benign pheochromocytomas. Thus, inactivation of the SDHD gene in hereditary paraganglioma is associated with a complete loss of mitochondrial complex II activity and with a high expression of angiogenic factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These clinical observations and the finding of increased expression of HIF targets in tumors with SDH mutations [9,10] have suggested the possibility that the VHL and SDH syndromes intersect at the molecular level.”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial complex II is a component of the electron transport chain, and mutations of SDHB or SDHD genes that abrogate the oxidoreductase function of complex II can cause pheochromocytomas [9,14,15].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, patients harbouring mutations in SDH have increased HIF-1α activity23,24 and circulating succinate25.”
From Succinate is an inflammatory signal that induces IL-1β through HIF-1α (2013) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, mutations in subunit SdhB, SdhC, or SdhD are linked to tumorigenesis in the form of autosome-dominant familial paragangliomas and pheochromocytomas (1, 3, 16, 19, 33).”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [19]
In the citing paper
“A relationship between SDH function and oxygen regulation has been suspected based on previous identification of increased expression of angiogenic factors in cases of SDH-mutant pheochromocytomas [9].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions
Higuchi, R., Fockler, C., Dollinger, G., & Watson, R. (1993) · Nature Biotechnology · doi:10.1038/nbt0993-1026 · Cited by 2,159 · cited 1×
“Relative quantitation of EPAS1 and VEGF gene expression was analyzed as a target-to-control expression ratio, using the standard curve method (Higuchi et al, 1993).”
MethodMitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 2×
“Mitochondria can act as O2 sensors by increasing the generation of reactive oxygen species, which are required for hypoxia-inducible factor 1 DNA–binding activity and subsequent increases in the synthesis of mRNA that encodes erythropoietin, vascular endothelial growth factor (VEGF), and glycolytic enzymes (Chandel et…”
BackgroundMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 6×
“The four exons of the SDHD gene (GenBank accession number AB 026906) were am- plified by PCR with primers and a procedure that has been described elsewhere (Baysal et al. 2000).”
BackgroundMethodInfluentialOxidative Phosphorylation at the fin de siècle
Saraste, M. (1999) · Science · doi:10.1126/science.283.5407.1488 · Cited by 1,313 · cited 2×
“Complex II or succinate-ubiquinone reductase (EC 1.3.99.1) is an important enzymatic complex crucial for both the tricarboxylic acid cycle and the aerobic respiratory chains of mitochondria (Saraste 1999).”
BackgroundInfluentialBiochemical and molecular investigations in respiratory chain deficiencies
Rustin, P., Chretien, D., Bourgeron, T., Gérard, B., Rötig, A., Saudubray, J. M., & Munnich, A. (1994) · Clinica Chimica Acta · doi:10.1016/0009-8981(94)90055-8 · Cited by 1,243 · cited 1×
“The activity of the respiratory-chain complexes was measured, as described elsewhere (Rustin et al. 1994).”
MethodSelf-citationAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 2×
“Then, several germline SDHD mutations were reported in families with paraganglioma (Badenhop et al. 2001; Milunsky et al. 2001) and in families with pheochromocytoma (Astuti et al. 2001a).”
BackgroundMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 2×
“The SDHC gene encoding the large subunit of cytochrome b in succinate-ubiquinone oxidoreductase was reported to correspond to the PGL3 gene (Niemann and Müller 2000; Niemann et al. 2001).”
BackgroundDifferential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
Gerber, H.-P., Condorelli, F., Park, J., & Ferrara, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23659 · Cited by 794 · cited 1×
“First, VEGF-R1 mRNA, which encodes the VEGF receptor induced in hypoxic conditions (Gerber et al. 1997), was found to be more abundant than VEGF-R2 mRNA.”
BackgroundBourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730 · cited 1×
“The causative mutation was identified in the SDHA gene encoding the flavoprotein of complex II, and the enzymatic defect was partial (Bourgeron et al. 1995).”
BackgroundSelf-citationNeurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells
SCHMECHEL, D., MARANGOS, P. J., & BRIGHTMAN, M. (1978) · Nature · doi:10.1038/276834a0 · Cited by 723 · cited 1×
“This result was expected, because NSE is considered an indicator of neuroendocrine differentiation (Schmechel et al. 1978).”
Background
Research works printed but not linked: 2
- Koreth, 1999, Chromosomes, 11q and cancer: a review, J Pathol, 187, 28, 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R · doi:10.1002/(sici)1096-9896(199901)187:1<28::aid-path166>3.0.co;2-r
- Pacheco-Ojeda, 1988, Carotid body at high altitudes, World J Surg, 12, 856
Cited by
Items 101–200 of 364
Cytopathies involving mitochondrial complex II
Ackrell, B. A. C. (2002) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(02)00012-2 · Cited by 86
Von Hippel-Lindau disease and endocrine tumour susceptibility
Woodward, E. R., & Maher, E. R. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.00683 · Cited by 87
“Phaeochromocytomas from SDHB and SDHD gene carriers demonstrate evidence of HIF activation and over-expression of hypoxia-inducible genes (Gimenez-Roqueplo et al. 2001, Pollard et al. 2005) and SDH inactivation has been shown in vitro to inhibit HIF-a prolyl hydroxylases leading to stabilisation…”
BackgroundBénit, P., Letouzé, É., Rak, M., Aubry, L., Burnichon, N., Favier, J., Gimenez‐Roqueplo, A., & Rustin, P. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.03.013 · Cited by 98
Self-citationRespiratory chain complex II as general sensor for apoptosis
Grimm, S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.09.009 · Cited by 82
Paraganglioma after Maternal Transmission of a Succinate Dehydrogenase Gene Mutation
Pigny, P., Vincent, A., Bauters, C. C., Bertrand, M., de Montpréville, V., Crepin, M., Porchet, N., & Caron, P. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1989 · Cited by 93
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel
Wojtovich, A. P., Smith, C. O., Haynes, C. M., Nehrke, K. W., & Brookes, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.007 · Cited by 83
“In these cases there is typically no detectable SDH activity in tumors [11].”
BackgroundPhysical Exercise and Epigenetic Modulation: Elucidating Intricate Mechanisms
Pareja-Galeano, H., Sanchis‐Gomar, F., & García‐Giménez, J. L. (2014) · Sports Medicine · doi:10.1007/s40279-013-0138-6 · Cited by 91
Mitochondrial heterogeneity in diseases
Chen, L., Zhou, M., Li, H., Liu, D., Liao, P., Yao, Z., Zhang, C., Zou, W., & Gao, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01546-w · Cited by 93
“345 In multiple cutaneous and uterine leiomyomata and in aggressive forms of renal cell cancer, fumarate hydratase (FH) heterogeneity is critical to tumor formation.”
BackgroundHead and Neck Paragangliomas: Value of Contrast-Enhanced 3D MR Angiography
Neves, F., Huwart, L., Jourdan, G., Reizine, D., Herman, P., Vicaut, É., & Guichard, J. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0948 · Cited by 85
“Mutations involved in paragangliomas have now been characterized, but the penetrance of the mutation is variable.(25,26) SRS and MR imaging are used to screen patients with hereditary paraganglioma genes.”
BackgroundSrirangalingam, U., Walker, L., Khoo, B. C. E., MacDonald, F., Gardner, D. S.-L., Wilkin, T. J., Skelly, R. H., George, E., Spooner, D. A., Monson, J. P., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03274.x · Cited by 93
Badenhop, R. F., Jansen, J. C., Fagan, P. A., Lord, R. S. A., Wang, Z. G., Foster, W. J., & Schofield, P. R. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.011551 · Cited by 86
Laurenti, G., & Tennant, D. A. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160099 · Cited by 91
Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriers
Eijkelenkamp, K., Osinga, T. E., Links, T. P., & van der Horst‐Schrivers, A. N. A. (2019) · Clinical Genetics · doi:10.1111/cge.13553 · Cited by 103
Metabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 87
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 84
“The first clue was based on the detection of strong hypoxic features in SDH-associated tumors (35).”
Genetics of pheochromocytomas and paragangliomas
Opocher, G., & Schiavi, F. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.05.001 · Cited by 77
The Genetics of Neuroendocrine Tumors
Öberg, K. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.005 · Cited by 75
Pheochromocytomas and paragangliomas: assessment of malignant potential
Korevaar, T. I. M., & Grossman, A. B. (2011) · Endocrine · doi:10.1007/s12020-011-9545-3 · Cited by 72
Morris, M. R., Maina, E., Morgan, N. V., Gentle, D., Astuti, D., Moch, H., Kishida, T., Yao, M., Schraml, P., Richards, F. M., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.011767 · Cited by 70
The basic science of glomus jugulare tumors
Heth, J. (2004) · Neurosurgical FOCUS · doi:10.3171/foc.2004.17.2.2 · Cited by 70
HIF and fumarate hydratase in renal cancer
Sudarshan, S., Linehan, W. M., & Neckers, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603547 · Cited by 71
“In concordance with this finding, in situ hybridisation studies revealed upregulation of VEGF transcripts in HLRCC uterine leiomyomas in comparison to normal myometrium (from HLRCC and non-HLRCC women) as well as sporadic uterine leiomyomas (Pollard et al, 2005a).”
BackgroundInfluentialEvolving concepts in pheochromocytoma and paraganglioma
Dahia, P. L. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198017.45982.06 · Cited by 69
Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate
Goncalves, J., Moog, S., Morin, A., Gentric, G., Müller, S., Morrell, A. P., Kľučková, K., Stewart, T. J., Andoniadou, C. L., Lussey‐Lepoutre, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2936 · Cited by 81
“In all cases, germline SDHx mutations are associated with loss of heterozygosity, which causes the complete loss of SDH function in the tumor (9) and a subsequent accumulation of its substrate, succinate (10).”
BackgroundSelf-citationMarden, J. H. (2013) · Molecular Ecology · doi:10.1111/mec.12534 · Cited by 73
Mito-Nuclear Communication by Mitochondrial Metabolites and Its Regulation by B-Vitamins
Janssen, J. J. E., Grefte, S., Keijer, J., & de Boer, V. C. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00078 · Cited by 72
Cellular oxygen sensing in health and disease
Mole, D. R., & Ratcliffe, P. J. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0632-x · Cited by 79
Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes
Bauters, C., Vantyghem, M., Leteurtre, E., Odou, M., Mouton, C., Porchet, N., Wemeau, J.-L., Proye, C., & Pigny, P. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.6.e75 · Cited by 69
The Genetic Basis of Pheochromocytoma
Gimm, O., Koch, C. A., Januszewicz, A., Opocher, G., & INeumann, H. P. H. (2003) · KARGER eBooks · doi:10.1159/000074657 · Cited by 70
Pheochromocytoma: The First Metabolic Endocrine Cancer
Jochmanová, I., & Pacák, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0606 · Cited by 70
“significantly more expressed in SDHx-mutated tumors compared with sporadic ones (68, 69).”
BackgroundProlyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 87
“…and pheochromocytomas, as well as a number of other malignancies, whereas FH inactivation occurs primarily in hereditary leiomyomatosis and RCC. 95 100 However, it has also been argued that, because PHDs have a tight binding affinity for 2OG, the activation of HIF in the SDH-or FH-deficient…”
BackgroundRice bran extract protects from mitochondrial dysfunction in guinea pig brains
Hagl, S., Kocher, A., Schiborr, C., Eckert, S. H., Ciobanu, I., Birringer, M., El‐Askary, H. I., Helal, A. M., Khayyal, M. T., Frank, J., et al. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.008 · Cited by 67
Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome
Settas, N., Faucz, F. R., & Stratakis, C. A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.07.018 · Cited by 70
“Loss of heterozygosity (LOH) in the tumor leads to complete loss of the enzymatic function of the SDH; therefore, the SDH subunit genes are classified as classical tumor suppressor genes (Gimenez-Roqueplo et al., 2001; GimenezRoqueplo et al., 2002; Gimm et al., 2000).”
BackgroundDuet, M., Sauvaget, E., Pételle, B., Rizzo, N., Guichard, J., Wassef, M., Cloirec, J. L., Herman, P., & Huy, P. T. B. (2003) · PubMed · Cited by 63
RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA
Gimenez‐Roqueplo, A., Burnichon, N., Amar, L., Favier, J., Jeunemaître, X., & Plouin, P. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04881.x · Cited by 66
Self-citationMutations of the SDHB and SDHD genes
Pawlu, C., Bausch, B., & Neumann, H. P. H. (2005) · Familial Cancer · doi:10.1007/s10689-004-4227-4 · Cited by 65
“Accordingly, expression of hypoxic-angiogenic responsive genes was shown for SDHB and SDHD mutations [4, 5].”
BackgroundSelak, M. A., Durán, R. V., & Gottlieb, E. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.05.015 · Cited by 59
Seo, Y., Ji, Y. W., Lee, S. M., Shim, J., Noh, H., Yeo, A., Park, C., Park, M. S., Chang, E., & Lee, H.-H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.260 · Cited by 64
“In addition, patients harboring mutations in succinate dehydrogenase demonstrated increased HIF-1a levels.(28,29) Thus, elevated levels of succinate may enhance HIF-1a activation in DE-induced LGs, and this was confirmed using ex vivo LG organ culture (Figure 3g).”
BackgroundRao, J. U., Engelke, U. F. H., Rodenburg, R. J., Wevers, R. A., Pacák, K., Eisenhofer, G., Qin, N., Küsters, B., Goudswaard, A. G., Lenders, J. W. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3922 · Cited by 67
Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions
Bargiela, D., Burr, S. P., & Chinnery, P. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.02.002 · Cited by 60
Genetic basis of phaeochromocytoma and paraganglioma
Benn, D. E., & Robinson, B. G. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.005 · Cited by 58
Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options
Nölting, S., Grossman, A. B., & Pacák, K. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1888 · Cited by 66
“For example, overexpression of HIF-2α has been described in patients with PCCs and PGLs with SDHB and SDHD mutations [29, 30].”
Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma
Cascón, A., Ruiz‐Llorente, S., Cebrián, A., Tellería, D., Rivero, J. C., Díez, J. J., Lopez-Ibarra, P. J., Jaunsolo, M. A., Benitez, J. J., & Robledo, M. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200829 · Cited by 62
Model animals for the study of oxidative stress from complex II
Ishii, T., Miyazawa, M., Onouchi, H., Yasuda, K., Hartman, P. S., & Ishii, N. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.016 · Cited by 65
“Arg46Gln) in a malignant PHEO with somatic terminal deletion of 1p [57,58].”
BackgroundResultSaito, Y., Tanaka, Y., Aita, Y., Ishii, K., Ikeda, T., Isobe, K., Kawakami, Y., Shimano, H., Hara, H., & Takekoshi, K. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00035.2011 · Cited by 57
“Furthermore, the VEGF expression and increased microvessel density evidenced by CD31 staining has been associated with an aggressive malignant phenotype (15, 43).”
BackgroundCarney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency
Pitsava, G., Settas, N., Faucz, F. R., & Stratakis, C. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.680609 · Cited by 61
“SDHx germline heterozygous inactivating mutations affect the protein function and predispose to hereditary neoplasms; subsequently, loss of heterozygosity (LOH) in the tumor level results in complete loss of SDH activity (14).”
BackgroundZheleznova, N. N., Yang, C., Ryan, R. P., Halligan, B. D., Liang, M., Greene, A. S., & Cowley, A. W. (2012) · Physiological Genomics · doi:10.1152/physiolgenomics.00060.2012 · Cited by 52
Succinate dehydrogenase-deficient gastrointestinal stromal tumors
Wang, Y., Gu, M.-L., & Ji, F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i8.2303 · Cited by 61
Succinate Dehydrogenase and Ribonucleic Acid Networks in Cancer and Other Diseases
Moreno, C., Santos, R. M., Burns, R., & Zhang, W. C. (2020) · Cancers · doi:10.3390/cancers12113237 · Cited by 62
“Interestingly, SDHB [22] and SDHD [34] mutations increased ROS production, which led to the onset of PGL and PCC through the stabilization of HIF mode of action.”
BackgroundThe Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy
Wu, J., Liu, N., Chen, J., Tao, Q., Li, Q., Li, J., Chen, X., & Peng, C. (2024) · Research · doi:10.34133/research.0351 · Cited by 71
“…cancer Inhibit the homologous recombination DNA repair pathway [118] Promoting cancer DNA hypermethylation [114] Increasing expression of HIF-1 α [116,117] Activating STAT3 and ERK1/2 by SUCNR1, up-regulating VEGF expression, and promoting angiogenesis [124] Increasing ROS production, activating…”
BackgroundSuccinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics
Her, Y. F., & Maher, L. J. (2015) · International Journal of Endocrinology · doi:10.1155/2015/296167 · Cited by 58
“Studying SDHB and SDHD mutations in families with PGL, Gimenez-Roqueplo and colleagues showed that PGL tumors accumulated succinate and the SDH complex was inactive [120].”
BackgroundOwens, K. M., Aykin-Burns, N., Dayal, D., Coleman, M. C., Domann, F. E., & Spitz, D. R. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.435 · Cited by 52
Current and upcoming mitochondrial targets for cancer therapy
Kim, H. K., Noh, Y. H., Nilius, B., Ko, K. S., Rhee, B. D., Kim, N., & Han, J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.006 · Cited by 55
“ETC II of the mitochondrial respiratory chain and activates the hypoxia-inducible transcription factor-1 α (HIF-1α) signaling pathway, leading to tumor growth and vascularization (Figure 2b) [37].”
BackgroundMultifaceted Roles of Mitochondrial Components and Metabolites in Metabolic Diseases and Cancer
Nakhle, J., Rodriguez, A., & Vignais, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124405 · Cited by 58
“The R22X nonsense SDHD mutation found in hereditary paraganglioma and pheochromocytoma generates a truncated SDHD protein of 21 amino acids (instead of 159), resulting in the loss of complex II electron transfer and enzymatic activities and in the activation of the HIF1α signaling pathway [64,65].”
BackgroundPhysical Exercise and Epigenetic Modulation: Elucidating Intricate Mechanisms
Sanchis-Gomar, H. P.-G., & a-Gimenez, J. G. ́. (2014) · Cited by 51
Marden, J. H., Fescemyer, H. W., Schilder, R. J., Doerfler, W. R., Vera, J. C., & Wheat, C. W. (2012) · Evolution · doi:10.1111/evo.12004 · Cited by 52
“…studies have linked rare heterozygous SDH loss-offunction mutations in humans to pseudohypoxia signaling and development of vascularized tumors (Gimenez-Roqueplo et al. 2001; Pollard et al. 2005; Selak et al. 2005; Smith et al. 2007; Baysal 2008; Burnichon et al. 2010; Puissegur et al. 2011).”
BackgroundPiantadosi, C. A., & Suliman, H. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709741200 · Cited by 50
Zantour, B., Guilhaume, B., Tissier, F., Louvel, A., Jeunemaître, X., Gimenez‐Roqueplo, A., & BERTAGNA, X. Y. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510433 · Cited by 49
Self-citationHIF Signaling Pathway in Pheochromocytoma and Other Neuroendocrine Tumors
Jochmanová, I., Zelinka, T., Widimsky, J., Jr., & Pacák, K. (2014) · Physiological Research · doi:10.33549/physiolres.932789 · Cited by 55
Dahia, P. L. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.023 · Cited by 56
Mitochondrial Alterations During Carcinogenesis
Wang, X., Peralta, S., & Moraes, C. T. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00004-6 · Cited by 49
“Tumors with either SDH subunit or FH mutations showed an activation of the HIF-1 pathway and high vascularity (Gimenez-Roqueplo et al., 2001; Pollard et al., 2005).”
BackgroundLemarié, A., & Grimm, S. (2009) · Mitochondrion · doi:10.1016/j.mito.2009.03.004 · Cited by 53
“Of note, there are some indications that complex II subunit mutations found in human tumours could also lead to complex II destabilisation (Douwes Dekker et al., 2003) or display a profoundly reduced complex II activity (Gimenez-Roqueplo et al., 2001, 2002).”
BackgroundSimi, L., Sestini, R., Ferruzzi, P., Gaglianò, M. S., Gensini, F., Mascalchi, M., Guerrini, L., Pratesi, C., Pinzani, P., Nesi, G., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030353 · Cited by 51
Rustin, P., & Kroemer, G. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_086 · Cited by 47
Self-citationThyroid-Associated Paragangliomas
Phitayakorn, R., Faquin, W. C., Wei, N., Barbesino, G., & Stephen, A. E. (2011) · Thyroid · doi:10.1089/thy.2010.0362 · Cited by 44
“Mutations in succinate dehydrogenase may activate an angiogenic pathway that ultimately leads to tumorigenesis (33).”
Role of HIF1 α Regulatory Factors in Stem Cells
Lee, H. J., Jung, Y. H., Choi, G. E., Kim, J. S., Chae, C. W., & Han, H. J. (2019) · International Journal of Stem Cells · doi:10.15283/ijsc18109 · Cited by 51
“tion of HIF1 in embryonic stem cells under normoxic conditions (76-78).”
BackgroundSDHC mutations in hereditary paraganglioma/pheochromocytoma
Müller, U., Troidl, C., & Niemann, S. (2005) · Familial Cancer · doi:10.1007/s10689-004-0621-1 · Cited by 46
“Studies of tumors caused by inactivation of SDHD demonstrated complete and selective loss of mitochondrial complex II enzymatic activity [17].”
BackgroundSuccinate at the Crossroad of Metabolism and Angiogenesis: Roles of SDH, HIF1α and SUCNR1
Atallah, R., Olschewski, A., & Heinemann, Á. (2022) · Biomedicines · doi:10.3390/biomedicines10123089 · Cited by 47
Span, P. N., Rao, J. U., Ophuis, S. B. J. O., Lenders, J. W. M., Sweep, F. C. G. J., Wesseling, P., Küsters, B., van Nederveen, F. H., de Krijger, R. R., Hermus, A. R. M. M., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0184 · Cited by 47
Zhou, Z., Ibekwe, E., & Chornenkyy, Y. (2018) · Antioxidants · doi:10.3390/antiox7010016 · Cited by 45
“To support this hypothesis, mutations in SDH subunits D and B in tumors from families with paragangliomas were found to activate the HIF1α pathway and be highly vascularized [118,119].”
BackgroundPuurand, M., Peet, N., Tein, A., Salupere, R., Sirotkina, M., Valle, J., Peetsalu, A., & Seppet, E. K. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2231-4 · Cited by 44
Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate
Hahn, N. M., Rečková, M., Liang Cheng, C., Baldridge, L. A., Cummings, O. W., & Sweeney, C. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9380 · Cited by 45
Tsang, V., Dwight, T., Benn, D. E., Meyer-Rochow, G. Y., Gill, A. J., Sywak, M. S., Sidhu, S., Veivers, D., Sue, C. M., Robinson, B. G., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0519 · Cited by 48
Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1¿ pathway in human ovarian cancer in vitro
Chen, L., Liu, T., Zhang, S., Zhou, J., Wang, Y., & Di, W. J. (2014) · Journal of Ovarian Research · doi:10.1186/s13048-014-0115-1 · Cited by 54
“Genetic analysis of hereditary paraganglioma reveals an activation of the hypoxia-response pathway [12].”
BackgroundGerometabolites: The pseudohypoxic aging side of cancer oncometabolites
MENENDEZ MENENDEZ, J., ALARCÓN, T., & Joven, J. (2014) · Cell Cycle · doi:10.4161/cc.28079 · Cited by 40
“1).(29-36) Succinate was initially found to impair PHD2, the α-ketoglutarate-dependent enzyme regulating HIFα stability, through product inhibition, and subsequent work confirmed that succinate could also inhibit the related enzyme PHD3.”
BackgroundBailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
“Moreover, paragangliomas in patients with SDHD mutations have increased levels of HIF-2α and angiogenic factors [24], and the transcriptional profile of phaeochromocytomas with mutations in SDH subunits is similar to those seen in VHL-mutant tumours [25].”
BackgroundPowerhouse down: Complex II dissociation in the respiratory chain
Hwang, M., Rohlena, J., Dong, L., Neužil, J., & Grimm, S. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.06.001 · Cited by 42
A novel G106D alteration of the SDHD gene in a pedigree with familial paraganglioma
Ogawa, K., Shiga, K., Saijo, S., Ogawa, T., Kimura, N., & Horii, A. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31444 · Cited by 40
Mapping of Succinate Dehydrogenase Losses in 2258 Epithelial Neoplasms
Miettinen, M., Sarlomo‐Rikala, M., McCue, P. A., Czapiewski, P., Langfort, R., Waloszczyk, P., Ważny, K., Biernat, W., Lasota, J. P., & Wang, Z. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31828bfdd3 · Cited by 41
Renard, L., Godfraind, C., Boon, L. M., & Vikkula, M. (2003) · Head & Neck · doi:10.1002/hed.10220 · Cited by 38
“It has been shown that the R22X SDHD mutation leads to overproduction of angiogenic factors, such as VEGF and EPAS1, which probably contribute to the increased angiogenesis of these tumors.(11) SDHD mutations have so far been identified in all four exons, without observed phenotype– genotype correlation.”
BackgroundStructural and functional consequences of succinate dehydrogenase subunit B mutations
Kim, E., Rath, E. M., Tsang, V., Duff, A. P., Robinson, B. G., Church, W. B., Benn, D. E., Dwight, T., & Clifton-Bligh, R. J. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0099 · Cited by 39
Oudijk, L., Gaal, J., & de Krijger, R. R. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9555-2 · Cited by 38
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas
Moog, S., Lussey‐Lepoutre, C., & Favier, J. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0346 · Cited by 45
Self-citationMitochondrial superoxide anion (O2·-) inducible "mev-1" animal models for aging research
Ishii, T., Miyazawa, M., Hartman, P. S., & Ishii, N. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.5.298 · Cited by 39
Daniel, E., Jones, R. N., Bull, M., & Newell-Price, J. D. C. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0595 · Cited by 37
Kitajima, S., Lee, K. L., Hikasa, H., Sun, W., Huang, R. Y., Yang, H. H., Matsunaga, S., Yamaguchi, T., Araki, M., Kato, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23010 · Cited by 35
“It is known that HIFs are also activated under normoxia by reactive oxygen species (ROS) [17], nitric oxide (NO) [18, 19] or mutations of a mitochondrial enzyme [20].”
BackgroundGenetic Testing for Pheochromocytoma-associated Syndromes
Pawlu, C., Bausch, B., Reisch, N., & Neumann, H. P. H. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81749-4 · Cited by 36
“The expression of hypoxic-angiogenic responsive genes was found in SDH mutations [19, 20], and may indicate a pathophysiology related to the models of VHL disease.”
BackgroundPhosphoglycerate Dehydrogenase: Potential Therapeutic Target and Putative Metabolic Oncogene
Zogg, C. K. (2014) · Journal of Oncology · doi:10.1155/2014/524101 · Cited by 39
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 37
“…found relatively more common HIF2a overexpression in VHL PHEOs and PGLs, whereas in SDHx-related tumors nuclear HIF1a staining was more prominent, Gimenez-Roqueplo et al. (2001, 2002) described overexpression of HIF2a and VEGF in patients with PHEOs and PGLs carrying SDHB and SDHD mutations…”
Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor
Koch, C. A., Rodbard, J. S., Brouwers, F. M., Eisenhofer, G., & Pacák, K. (2003) · Endocrine Practice · doi:10.4158/ep.9.4.310 · Cited by 35
Fliedner, S. M. J., Kaludercic, N., Jiang, X.-S., Hansíková, H., Hájková, Z., Sládková, J., Limpuangthip, A., Backlund, P. S., WESLEY, R. A., Martiniova, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040949 · Cited by 36
“First, its function as complex II in the electron transfer chain of the OXPHOS is impaired, resulting in decreased activity in SDHB and D [15,16,17,18], and possibly in A and C, mutations.”
BackgroundMechanisms of acute oxygen sensing by the carotid body: Lessons from genetically modified animals
Ortega‐Sáenz, P., Pascual, A., Piruat, J. I., & López‐Barneo, J. (2007) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2007.02.009 · Cited by 40
Takekoshi, K., Isobe, K., Yashiro, T., Hara, H., Ishii, K., Kawakami, Y., Nakai, T., & Okuda, Y. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.07.036 · Cited by 34
Zhang, D., Wang, W., Xiang, B., Li, N., Huang, S., Zhou, W., Sun, Y., Wang, X., Ma, J., Li, G., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-0781-4 · Cited by 36
Warburg and Krebs and related effects in cancer
Unterlass, J. E., & Curtin, N. J. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.4 · Cited by 37
Active succinate dehydrogenase (SDH) and lack of SDHD mutations in sporadic paragangliomas.
Braun, S., Riemann, K., Kupka, S., Leistenschneider, P., Sotlar, K., Schmid, H., & Blin, N. (2005) · PubMed · Cited by 38
Saito, Y., Ishii, K., Aita, Y., Ikeda, T., Kawakami, Y., Shimano, H., Hara, H., & Takekoshi, K. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1738-3 · Cited by 39
“These results indicate that PC12 cells with SDH deficiency may have utility as an in vitro model of HPPS [5, 7].”
BackgroundOxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma
Her, Y. F., Nelson-Holte, M. H., & Maher, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127471 · Cited by 35
“It has been reported that SDHB protein loss accompanies any disruption of the SDH complex in PGLs [43,44].”
BackgroundInfluentialPai, R. B., Manipadam, M. T., Singh, P., Ebenazer, A., Samuel, P., & Rajaratnam, S. (2014) · Apmis · doi:10.1111/apm.12269 · Cited by 33
Riemann, K., Sotlar, K., Kupka, S., Braun, S., Zenner, H., Preyer, S., Pfister, M., Pusch, C. M., & Blin, N. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2003.10.013 · Cited by 33
Corrado, M., Scorrano, L., & Campello, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8727 · Cited by 34
“First, the concentration of circulating succinate (and HIF1α activity) in patients with tumours harbouring mutations in SDH is higher than in the healthy population [54],[97]; second, succinate can signal through its receptor GPR91 on dendritic cells in order to modulate the immune response [98].”
Background
Metadata
- Authors
- Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Mourad, J.-J., Plouin, P.-F., Corvol, P., Rötig, A., & Jeunemaitre, X.
- Affiliations
- Inserm (FR)
- Hôpital Saint-Michel (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 69
- Issue
- 6
- Pages
- 1186-1197
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1235531
- OpenAlex
- W1975918337
- Cited by
- 364
- References
- 44
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 12 · 2022: 8 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 9 · 2017: 12 · 2016: 15 · 2015: 14 · 2014: 32 · 2013: 24 · 2012: 19
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4248 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- hereditary paraganglioma, succinate dehydrogenase, cytochrome b, mitochondrial respiratory chain, loss of heterozygosity, pheochromocytoma, carotid body paraganglioma, hypoxia pathway, angiogenic factors, vascular endothelial growth factor, EPAS1, tumor angiogenesis, SDHC, SDHB
- MeSH terms
- Adult, Aged, Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 11, Consanguinity, Electron Transport, Female, Humans, Immunohistochemistry, Male, Middle Aged, Mitochondria, Oxygen, Paraganglioma, Pedigree, RNA, Messenger, Succinate Dehydrogenase, Cell Hypoxia, Gene Expression, In Situ Hybridization, Germ-Line Mutation, Codon, Nonsense, Loss of Heterozygosity, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.